Advancements in portable instruments based on affinity-capture-migration and affinity-capture-separation for use in clinical testing and life science applications

Guzman, Norberto A.; Guzman, Daniel E.; Blanc, Timothy

doi:10.1016/j.chroma.2023.464109

Cited by 6 publications

(7 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evolving technology in healthcare continues to shape the way we provide care to patients. Advances in artificial intelligence, data generated in proteomics research, and the more mainstream use of telemedicine allows patients, families, and their caregivers to improve diagnostic quality, anywhere in the world [95,118,155,156,169]. Sputum tests offer hope in determining protein and nucleic acid biomarkers for the diagnosis of respiratory infectious diseases, pulmonary diseases, and lung cancer far in advance of clinical symptoms [33,170].…”

Section: Discussion and Future Perspectivementioning

confidence: 99%

“…LFIAs, founded on an affinity-capture-migration technology occasionally yield false-negative or false-positive misdiagnoses, yet they continue to be used as a screening tool [92][93][94][95]. Conversely, immunoaffinity capillary electrophoresis (IACE), based on the principle of an affinity-captureseparation or a two-dimensional technology, are popular tests due to their ability to confirm results [62,[95][96][97][98][99][100]. Even if there are doubts about the biomarker(s) separated by a capillary electrophoresis (CE) (electropherogram), the CE outlet terminal can be coupled to a mass spectrometer that also validate findings.…”

Section: Potential Use Of Point-of-care Platforms For the Screening O...mentioning

confidence: 99%

See 1 more Smart Citation

Human Sputum Proteomics: Advancing Non-Invasive Diagnosis of Respiratory Diseases with Enhanced Biomarker Analysis Methods

Guzman,

Guzman

2024

Preprint

View full text Add to dashboard Cite

Many ailments can be diagnosed while they are asymptomatic, meaning that the patient has no signs or symptoms of a progressing disease. If caught in their initial stage of formation, these maladies can be effectively treated, leading to successful outcomes; curative therapies can halt illnesses from advancing, thus improving the quality of life, and long-term survival of the patient. Still cutting-edge upgrades in precision technologies are necessary for early, reliable, affordable, and rapid disease detection, but also are vital for the well-being of people and the future of global public health. The emerging role and utility of non-invasive and repeatable diagnostic test approaches for detection of health conditions has been liquid biopsies based on genomic biomarkers. As such, biological fluids permit any measurable molecular indicator or signature (e.g., proteins), to provide valuable information on individual’s wellness and/or disease. Among the bodily secretions used for non-invasive diagnostics is sputum, a complex viscous gel-like biopolymeric network, that has gained growing recognition as a rich source of biomarkers of airway infections, pulmonary diseases, and serves as a determinant to reveal other illnesses. As per the World Health Organization, the burden of respiratory conditions is exacerbated by factors, ranging from considerable subjection to air pollution and occupational contaminants, to tobacco smoking and second-hand smoke, in addition to poor socio-economic status. Due to the likely increase of these determinants, respiratory tract ailments are on the rise, affecting the health of many individuals, in addition to putting stress on healthcare facilities and services worldwide. We therefore highlight the need to use expectorated or induced sputum specimens as a routine sample source for testing valuable protein biomarkers to diagnose these chronic maladies, to predict inflammation and disease progression, as well as monitor the effectiveness of treatments. Further, we discuss the urgency for fast and reliable point-of-care methods to detect and quantify crucial protein biomarkers in sputum specimens, and limitations faced when dealing with their complex matrices.

show abstract

Section: Discussion and Future Perspectivementioning

confidence: 99%

Section: Potential Use Of Point-of-care Platforms For the Screening O...mentioning

confidence: 99%

Human Sputum Proteomics: Advancing Non-Invasive Diagnosis of Respiratory Diseases with Enhanced Biomarker Analysis Methods

Guzman,

Guzman

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Evolving technology in healthcare continues to shape the way we provide care to patients. Advances in artificial intelligence, data generated in proteomics research, and the more mainstream use of telemedicine allow patients, families, and their caregivers to improve diagnostic quality anywhere in the world [103,126,163,164,177]. Sputum tests offer hope in determining protein and nucleic acid biomarkers for the diagnosis of respiratory infectious diseases, pulmonary diseases, and lung cancer far in advance of clinical symptoms [33,178].…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

“…LFIAs, founded on an affinity-capture-migration technology, occasionally yield falsenegative or false-positive misdiagnoses, yet they continue to be used as a screening tool [100][101][102][103]. Conversely, immunoaffinity capillary electrophoresis (IACE), based on the principle of an affinity-capture-separation or a two-dimensional technology, is a popular test due to its ability to confirm results [70,[103][104][105][106][107][108]. Even if there are doubts about the biomarker(s) separated by capillary electrophoresis (CE) (electropherogram), the CE outlet terminal can be coupled to a mass spectrometer that also validates findings.…”

Section: Potential Use Of Point-of-care Platforms For the Screening O...mentioning

confidence: 99%

Human Sputum Proteomics: Advancing Non-Invasive Diagnosis of Respiratory Diseases with Enhanced Biomarker Analysis Methods

Guzman,

Guzman

2024

IJTM

Self Cite

View full text Add to dashboard Cite

Many ailments can be diagnosed while they are asymptomatic, meaning that the patient has no signs or symptoms of a progressing disease. If caught in their initial stage of formation, these disorders can be effectively treated, leading to successful outcomes; curative therapies can halt illnesses from advancing, thus improving the quality of life and long-term survival of the patient. Still, cutting-edge upgrades in precision technologies are necessary for early, reliable, affordable, and rapid disease detection, but also vital for the well-being of people and the future of global public health. The emerging role and utility of non-invasive and repeatable diagnostic test approaches for the detection of health conditions have been exemplified by liquid biopsies based on genomic biomarkers. As such, biological fluids permit any measurable molecular indicator or signature (e.g., proteins) to provide valuable information on an individual’s wellness and/or disease. Among the bodily secretions used for non-invasive diagnostics is sputum, a complex viscous gel-like biopolymeric network that has gained growing recognition as a rich source of biomarkers of airway infections and pulmonary diseases, and serves as a determinant to reveal other illnesses. As per the World Health Organization, the burden of respiratory conditions is exacerbated by factors ranging from considerable subjection to air pollution and occupational contaminants to tobacco smoking and second-hand smoke, in addition to poor socio-economic status. Due to the likely increase in these determinants, respiratory tract ailments are on the rise, affecting the health of many individuals, in addition to putting stress on healthcare facilities and services worldwide. The aim of this study was to perform a narrative review of sputum constituents with an emphasis on proteins and glycoproteins assessed as possible biomarkers of lung and other organ diseases. A search was conducted using mucus, sputum proteomics, sputum biomarkers, and point-of-care testing as keywords employing Google, PubMed (MEDLINE), and Web of Science, selecting the most referenced and related papers of the last decade. We, therefore, highlight the need to use expectorated or induced sputum specimens as a routine sample source for testing valuable protein biomarkers to diagnose these chronic disorders, predict inflammation and disease progression, as well as monitor the effectiveness of treatments. Further, we discuss the urgent need for fast and reliable point-of-care methods to detect and quantify crucial protein biomarkers in sputum specimens, and the limitations faced when dealing with their complex matrices.

show abstract

“…The swab was introduced into the nostril as instructed by the manufacturer protocol, followed by the insertion of the swab into a tube containing an extraction buffer carrying a surfactant. After the appropriate extraction procedure and mixing of the sample material absorbed and retained onto the swab, three to four drops of the solution were removed from the squeezable plastic tube and gently applied to the sample well of the platform or cassette of the manufacturer's test kits, known as the sample pad 17 . The entire procedure to perform the LFIA tests [17][18][19][20] were carried out in our laboratory at a temperature of approximately 25-degrees Celsius.…”

Section: Conventional Protocol Applied To Repeat the Antigen-based Testmentioning

confidence: 99%

A COVID-19 Infection with Positive Sputum and Negative Nasopharyngeal/Oropharyngeal Rapid Antigen-Based Testing: A Case Report and Pilot Study

Guzman,

Guzman

2023

MCCRJ

View full text Add to dashboard Cite

Current COVID-19 antigen testing is primarily carried out by obtaining a specimen via nasopharyngeal/oropharyngeal swab and performing a rapid lateral flow immunoassay (LFIA) disposable micro-device or related immunoassays. In this case report and pilot study, we propose the application of a modified pretreatment antigen-based method for sputum, using at least one detergent and one digestive enzyme. This method exposes hidden or masked antigenic sites of viral specimens or lingering fragments of viral proteins present in a complex biological matrix using a home-based rapid immunoassay for COVID-19. The modified technique can enhance detection sensitivity of LFIA by making visible the resultant test band, from viralcontaining sputum samples, that would otherwise not be seen.

show abstract

Advancements in portable instruments based on affinity-capture-migration and affinity-capture-separation for use in clinical testing and life science applications

Cited by 6 publications

References 166 publications

Human Sputum Proteomics: Advancing Non-Invasive Diagnosis of Respiratory Diseases with Enhanced Biomarker Analysis Methods

Human Sputum Proteomics: Advancing Non-Invasive Diagnosis of Respiratory Diseases with Enhanced Biomarker Analysis Methods

Human Sputum Proteomics: Advancing Non-Invasive Diagnosis of Respiratory Diseases with Enhanced Biomarker Analysis Methods

A COVID-19 Infection with Positive Sputum and Negative Nasopharyngeal/Oropharyngeal Rapid Antigen-Based Testing: A Case Report and Pilot Study

Contact Info

Product

Resources

About